Catherine Stehman-Breen
Chief Tech/Sci/R&D Officer bei DYNE THERAPEUTICS, INC.
Vermögen: 4 Mio $ am 31.03.2024
Profil
Catherine Stehman-Breen is currently the Chief Executive Officer & Director at Chroma Medicine, Inc., an Independent Director at Generation Bio Co., an Independent Director at Tenaya Therapeutics, Inc., the Director & Chief Medical Officer at Dyne Therapeutics, Inc., and an Advisor at Atlas Venture Advisors, Inc. and Atlas Venture Life Science Advisors LLC.
She is also an Associate Professor at UW School of Public Health.
In her former positions, Dr. Stehman-Breen served as the Chairman-United States Renal Data System at the National Institute of Diabetes & Digestive & Kidney Diseases.
She was also the Vice President-Global Development at Amgen, Inc. from 2003 to 2015, the VP-Clinical Development & Regulatory Affairs at Regeneron Pharmaceuticals, Inc. from 2015 to 2017, the Chief Medical Officer at Sarepta Therapeutics, Inc. in 2017, the Chief Research & Development Officer at Obsidian Therapeutics, Inc. from 2019 to 2020, and the Chief Medical Officer at Disarm Therapeutics, Inc. from 2018 to 2019.
Dr. Stehman-Breen obtained her graduate degree from the University of Washington in 1996.
She completed her undergraduate degree at Colby College in 1985.
She also holds graduate and doctorate degrees from The University of Chicago, which she received in 1990.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
DYNE THERAPEUTICS INC
0,14% | 24.05.2023 | 115 713 ( 0,14% ) | 3 Mio $ | 31.03.2024 |
GENERATION BIO CO.
0,07% | 08.06.2023 | 47 523 ( 0,07% ) | 193 419 $ | 31.03.2024 |
| 31.03.2024 | 8 125 ( 0,01% ) | 42 494 $ | 31.03.2024 |
Aktive Positionen von Catherine Stehman-Breen
| Unternehmen | Position | Beginn |
|---|---|---|
| GENERATION BIO CO. | Director/Board Member | 01.12.2017 |
| DYNE THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 28.06.2019 |
| TENAYA THERAPEUTICS, INC. | Director/Board Member | 01.06.2020 |
Chroma Medicine, Inc.
 Chroma Medicine, Inc. Pharmaceuticals: MajorHealth Technology Chroma Medicine, Inc. is a biotechnology company that pioneers a new class of genomic medicines using epigenetics to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company is based in Cambridge, MA and has subsidiaries in Italy. The company's modular platform enables the development of medicines that can address a wide range of complex diseases, whether they require silencing, activation, or targeting multiple genes at once. Chroma Medicine was founded by the world's foremost experts in genomic research and is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development. Catherine Stehman-Breen has been the CEO of the company since 2020. | Chief Executive Officer | 01.12.2020 |
| UW School of Public Health | Corporate Officer/Principal | - |
Atlas Venture Advisors, Inc.
 Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Consultant / Advisor | 01.03.2018 |
Atlas Venture Life Science Advisors LLC
 Atlas Venture Life Science Advisors LLC Investment ManagersFinance Atlas Venture Life Science Advisors LLC (Atlas Venture) is a venture capital firm founded in 2014. The firm is headquartered in Cambridge, Massachusetts. | Consultant / Advisor | 01.03.2018 |
Ehemalige bekannte Positionen von Catherine Stehman-Breen
| Unternehmen | Position | Ende |
|---|---|---|
Obsidian Therapeutics, Inc.
 Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01.12.2020 |
Disarm Therapeutics, Inc.
 Disarm Therapeutics, Inc. BiotechnologyHealth Technology Disarm Therapeutics, Inc. engages in the development of therapeutics to treat patients with neurological diseases. It includes multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies. The company was founded by Jason Rhodes, Jeffrey Milbrandt, Raul Krauss, Aaron DiAntonio, and Rajesh Devraj on October 21, 2016 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01.07.2019 |
| ░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Catherine Stehman-Breen
| University of Washington | Graduate Degree |
| Colby College | Undergraduate Degree |
| The University of Chicago | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 6 |
|---|---|
| AMGEN INC. | Health Technology |
| REGENERON PHARMACEUTICALS, INC. | Health Technology |
| SAREPTA THERAPEUTICS, INC. | Health Technology |
| GENERATION BIO CO. | Health Technology |
| TENAYA THERAPEUTICS, INC. | Health Technology |
| DYNE THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 6 |
|---|---|
Atlas Venture Advisors, Inc.
Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Finance |
| National Institute of Diabetes & Digestive & Kidney Diseases | Government |
Atlas Venture Life Science Advisors LLC
Atlas Venture Life Science Advisors LLC Investment ManagersFinance Atlas Venture Life Science Advisors LLC (Atlas Venture) is a venture capital firm founded in 2014. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | Health Technology |
Disarm Therapeutics, Inc.
Disarm Therapeutics, Inc. BiotechnologyHealth Technology Disarm Therapeutics, Inc. engages in the development of therapeutics to treat patients with neurological diseases. It includes multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies. The company was founded by Jason Rhodes, Jeffrey Milbrandt, Raul Krauss, Aaron DiAntonio, and Rajesh Devraj on October 21, 2016 and is headquartered in Cambridge, MA. | Health Technology |
Chroma Medicine, Inc.
Chroma Medicine, Inc. Pharmaceuticals: MajorHealth Technology Chroma Medicine, Inc. is a biotechnology company that pioneers a new class of genomic medicines using epigenetics to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company is based in Cambridge, MA and has subsidiaries in Italy. The company's modular platform enables the development of medicines that can address a wide range of complex diseases, whether they require silencing, activation, or targeting multiple genes at once. Chroma Medicine was founded by the world's foremost experts in genomic research and is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development. Catherine Stehman-Breen has been the CEO of the company since 2020. | Health Technology |
